MITSUBISHI TANABE PHARMA CANADA CONCLUDES LETTER OF INTENT WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSION (EDARAVONE)

TORONTO, July 20, 2023 /CNW/ - Mitsubishi Tanabe Pharma Canada (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that it has entered into a Letter of Intent with the pan-Canadian

Related Keywords

Canada ,Toronto ,Ontario ,United States ,South Korea ,Japan ,Canadians ,America ,Canadian ,Tammy Moore ,Andy Zylak ,Tanabe Pharma America Inc ,Mitsubishi Tanabe Pharma Corporation ,Health Canada ,Mitsubishi ,Mitsubishi Chemical Group ,Canadian Pharmaceutical Alliance ,Twitter ,Drug Administration ,Mitsubishi Tanabe Pharma Canada Inc ,Linkedin ,Mitsubishi Tanabe Pharma America Inc ,Facebook ,Society Of Canada ,Health Canada On ,Mitsubishi Tanabe Pharma Canada ,Mitsubishi Tanabe Pharma America ,Oral Suspension ,Tanabe Pharma America ,Jersey City ,Tanabe Pharma Canada ,